EUVIMEDEUVIMED entdecken
Editorial

Worthwhile to whom? Public expectations and the value of lecanemab

Kenichiro Sato iD

Psychiatry and Clinical Neurosciences · 09.11.2026

DOI: 10.1111/pcn.70171 ↗

Kurz gefasst

Editorial in der Zeitschrift Psychiatry and Clinical Neurosciences, online erschienen am 09.11.2026. Verfasst von Kenichiro Sato. Beteiligte Einrichtung: Dementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan. Die Arbeit nennt 3 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Dementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan.

ORCID-Profile: Kenichiro Sato

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Sato, K. (2026). Worthwhile to whom? Public expectations and the value of lecanemab. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.70171

Vancouver

Sato K. Worthwhile to whom? Public expectations and the value of lecanemab. Psychiatry and Clinical Neurosciences. 2026. doi:10.1111/pcn.70171

BibTeX
@article{Sato2026,
  author = {Sato, Kenichiro},
  title = {Worthwhile to whom? Public expectations and the value of lecanemab},
  journal = {Psychiatry and Clinical Neurosciences},
  year = {2026},
  doi = {10.1111/pcn.70171}
}
Kostenlos starten →